Related Experiment Videos
Primary and secondary stroke prevention in atrial fibrillation
1Department of Neurology, Hennepin County Medical Center and the University of Minnesota, Minneapolis 55415, USA.
Insights
Atrial fibrillation increases stroke risk, but warfarin and aspirin offer significant protection. Individualized therapy is key to balancing stroke prevention with bleeding risks in older adults.
Area of Science:
- Cardiology
- Neurology
- Geriatrics
Background:
- Atrial fibrillation affects 6% of adults over 65, causing substantial stroke burden.
- Strokes in atrial fibrillation patients are often severe with poor long-term outcomes.
- Current treatments like warfarin and aspirin reduce stroke rates by 70% and 20%, respectively.
Purpose of the Study:
- To highlight the importance of risk stratification in atrial fibrillation patients.
- To guide individualized antithrombotic therapy decisions.
- To address the gap between scientific advancement and clinical application.
Main Methods:
- Review of modern clinical trials on antithrombotic therapy in atrial fibrillation.
- Analysis of stroke risk heterogeneity among patients.
- Discussion of balancing thromboembolic and bleeding risks.
Main Results:
- Warfarin demonstrates a ~70% reduction in stroke rate.
- Aspirin shows approximately a 20% stroke rate reduction.
- Significant variability in annual stroke risk (average 4-5%) exists within the atrial fibrillation population.
Conclusions:
- Risk stratification is crucial for optimizing antithrombotic therapy in atrial fibrillation.
- Individualized treatment balances stroke prevention with bleeding risks and patient preferences.
- Widespread education is needed to improve the application of evidence-based practices.
Abstract:
Atrial fibrillation, with a prevalence of 6% in those over 65 years, is responsible for 75-100 x 10(3) strokes each year in the United States. These strokes are more severe and have less favorable long-term prognosis than strokes due to other mechanisms. Modern trials show that warfarin reduces stroke rate by about 70% and aspirin by about 20%. Although average annual stroke rate among atrial fibrillation patients is about 4-5%, considerable risk heterogeneity exists. The goal of risk stratification is to differentiate patients with risk high enough to justify warfarin from those whose risk is so low that they are better off on aspirin or even no antithrombotic therapy. Ideal antithrombotic therapy is individualized, balancing risks of thromboembolism versus bleeding on antithrombotic therapy, and considering patient preferences. Although the science has advanced significantly in the past decade, application has lagged behind. Much benefit will potentially accrue from broad education efforts.